About Miragen Therapeutics (NASDAQ:MGEN)
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone303-531-5952
Debt
Debt-to-Equity Ratio0.26%
Current Ratio13.33%
Quick Ratio13.33%
Price-To-Earnings
Trailing P/E Ratio-4.70
Forward P/E Ratio-5.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales48.95
Cash FlowN/A
Price / CashN/A
Book Value$1.73 per share
Price / Book3.75
Profitability
EPS (Most Recent Fiscal Year)($1.38)
Net Income$-26,510,000.00
Net Margins-662.30%
Return on Equity-63.57%
Return on Assets-51.14%
Miscellaneous
Employees65
Outstanding Shares30,170,000
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics Inc. (NASDAQ:MGEN) released its quarterly earnings data on Wednesday, March, 14th. The medical research company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.04. The medical research company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.22 million. Miragen Therapeutics had a negative net margin of 662.30% and a negative return on equity of 63.57%. View Miragen Therapeutics' Earnings History.
What price target have analysts set for MGEN?
9 analysts have issued twelve-month target prices for Miragen Therapeutics' shares. Their forecasts range from $13.00 to $29.00. On average, they anticipate Miragen Therapeutics' share price to reach $17.1875 in the next twelve months. View Analyst Ratings for Miragen Therapeutics.
What are Wall Street analysts saying about Miragen Therapeutics stock?
Here are some recent quotes from research analysts about Miragen Therapeutics stock:
- 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (4/18/2018)
- 2. Cann analysts commented, "MiRagen Therapeutics announced today positive new interim data from its phase I clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented on February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California. These positive results support MiRagen’s plans to initiate a phase II study of MRG-106 in CTCL in the second half of 2018. The data released today, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials." (2/2/2018)
Who are some of Miragen Therapeutics' key competitors?
Some companies that are related to Miragen Therapeutics include Utah Medical Products (UTMD), Cambian Group (CMBN), Durect (DRRX), Strongbridge Biopharma (SBBP), Idera Pharmaceuticals (IDRA), Corbus Pharmaceuticals (CRBP), Antares Pharma (ATRS), GTX (GTXI), Quanterix (QTRX), Solid Biosciences (SLDB), Clearside Biomedical (CLSD), Cellular Biomedicine (CBMG), Dermira (DERM), Pieris Pharmaceuticals (PIRS), SafeStitch Medical (TRXC), NantHealth (NH), Endologix (ELGX) and Adverum Biotechnologies (ADVM).
Has Miragen Therapeutics been receiving favorable news coverage?
Press coverage about MGEN stock has been trending somewhat positive on Friday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Miragen Therapeutics earned a news sentiment score of 0.19 on Accern's scale. They also gave media coverage about the medical research company an impact score of 46.53 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Miragen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of MGEN stock can currently be purchased for approximately $6.49.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $193.71 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 303-531-5952 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (MGEN)
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Miragen Therapeutics (NASDAQ:MGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Miragen Therapeutics in the last 12 months. Their average twelve-month price target is $17.1875, suggesting that the stock has a possible upside of 164.83%. The high price target for MGEN is $29.00 and the low price target for MGEN is $13.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.1875 | $18.0833 | $17.90 | $23.00 |
| Price Target Upside: | 164.83% upside | 140.79% upside | 122.64% upside | 144.16% upside |
Miragen Therapeutics (NASDAQ:MGEN) Consensus Price Target History
Miragen Therapeutics (NASDAQ:MGEN) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Miragen Therapeutics (NASDAQ:MGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Miragen Therapeutics (NASDAQ MGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 18.98%
Miragen Therapeutics (NASDAQ MGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/13/2018 | Adam Scott Levy | Insider | Buy | 9,090 | $5.50 | $49,995.00 | 10,540 |  |
| 2/13/2018 | Bruce Booth | Director | Buy | 545,454 | $5.50 | $2,999,997.00 | | |
| 12/20/2017 | Thomas E. Hughes | Director | Sell | 12,000 | $8.00 | $96,000.00 | | |
| 6/22/2017 | Adam Scott Levy | Insider | Buy | 200 | $7.55 | $1,510.00 | 200 | |
| 3/10/2017 | Kyle Lefkoff | Director | Sell | 5,800 | $14.34 | $83,172.00 | | |
| 3/8/2017 | Kyle Lefkoff | Director | Sell | 15,000 | $15.40 | $231,000.00 | | |
| 2/28/2017 | Kyle Lefkoff | Director | Sell | 10,258 | $13.89 | $142,483.62 | | |
| 2/23/2017 | Kyle Lefkoff | Director | Sell | 5,902 | $14.14 | $83,454.28 | | |
| 11/20/2015 | Samuel D. Riccitelli | CEO | Buy | 14,000 | $0.79 | $11,060.00 | 345,130 | |
(Data available from 1/1/2013 forward)
Miragen Therapeutics (NASDAQ MGEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Miragen Therapeutics (MGEN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:00 AM |
| Miragen Therapeutics (MGEN) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - April 16 at 12:02 PM |
| Head-To-Head Analysis: Miragen Therapeutics (MGEN) vs. The Competition
www.americanbankingnews.com - April 15 at 11:14 PM |
| Miragen Therapeutics Inc. (MGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 9:57 AM |
| Head to Head Comparison: Miragen Therapeutics (MGEN) versus Its Rivals
www.americanbankingnews.com - April 12 at 9:51 AM |
| Financial Review: Miragen Therapeutics (MGEN) vs. Its Competitors
www.americanbankingnews.com - April 12 at 1:15 AM |
| Miragen Therapeutics (MGEN) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - April 10 at 5:03 PM |
| Miragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 9:44 AM |
| Miragen Therapeutics' (MGEN) "Hold" Rating Reiterated at Cowen
www.americanbankingnews.com - April 9 at 6:02 AM |
 | Form 8-K MIRAGEN THERAPEUTICS, For: Apr 03
www.streetinsider.com - April 8 at 3:10 PM |
| Financial Survey: Miragen Therapeutics (MGEN) and Its Rivals
www.americanbankingnews.com - April 7 at 1:26 PM |
| Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Post Quarterly Sales of $1.17 Million
www.americanbankingnews.com - April 6 at 1:56 AM |
| Miragen Therapeutics (MGEN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:52 PM |
| Miragen Therapeutics (MGEN) vs. Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 5 at 3:08 AM |
| -$0.26 EPS Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter
www.americanbankingnews.com - April 4 at 11:10 PM |
| Miragen Therapeutics, Inc. (MGEN) to Post Q1 2018 Earnings of ($0.27) Per Share, B. Riley Forecasts
www.americanbankingnews.com - March 30 at 6:52 AM |
| Head to Head Review: Miragen Therapeutics (MGEN) vs. Its Peers
www.americanbankingnews.com - March 29 at 5:24 PM |
| Miragen Therapeutics (MGEN) Research Coverage Started at Jefferies Group
www.americanbankingnews.com - March 29 at 9:18 AM |
| Wedbush Reaffirms "Outperform" Rating for Miragen Therapeutics (MGEN)
www.americanbankingnews.com - March 28 at 8:06 AM |
| miRagen Therapeutics (MGEN) Reports Initiation of Phase 1 Clinical Trial of MRG-110
www.streetinsider.com - March 28 at 5:33 AM |
 | miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110
finance.yahoo.com - March 27 at 3:15 PM |
| Wedbush Analysts Lift Earnings Estimates for Miragen Therapeutics, Inc. (MGEN)
www.americanbankingnews.com - March 23 at 7:46 AM |
| Miragen Therapeutics (MGEN) Receives New Coverage from Analysts at Deutsche Bank
www.americanbankingnews.com - March 22 at 8:42 PM |
| Miragen Therapeutics, Inc. Expected to Earn FY2022 Earnings of ($0.96) Per Share (MGEN)
www.americanbankingnews.com - March 22 at 5:54 PM |
| Miragen Therapeutics, Inc. (MGEN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 21 at 10:45 AM |
 | Miragen: Our Take On This RNA Play - Miragen Therapeutics, Inc ... - Seeking Alpha
seekingalpha.com - March 19 at 3:04 PM |
| Q1 2018 Earnings Forecast for Miragen Therapeutics, Inc. Issued By B. Riley (MGEN)
www.americanbankingnews.com - March 19 at 1:53 AM |
| Miragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2019 Earnings of ($0.29) Per Share
www.americanbankingnews.com - March 16 at 12:56 PM |
| Miragen Therapeutics (MGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 15 at 1:26 PM |
 | miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 15 at 5:11 AM |
| miRagen Therapeutics' (MGEN) CEO William Marshall on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 5:11 AM |
| miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 5:11 AM |
| Miragen Therapeutics (MGEN) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - March 9 at 3:23 PM |
| UPDATE: Evercore ISI Starts miRagen Therapeutics (MGEN) at ... - StreetInsider.com
www.streetinsider.com - March 9 at 3:15 PM |
| miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 3:07 PM |
| miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 14, 2018
finance.yahoo.com - March 7 at 3:07 PM |
| miRagen Therapeutics to Participate in Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 3:20 PM |
| miRagen Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 5 at 3:20 PM |
| $1.22 Million in Sales Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter
www.americanbankingnews.com - March 3 at 3:02 AM |
| Brokerages Expect Miragen Therapeutics, Inc. (MGEN) to Announce -$0.32 EPS
www.americanbankingnews.com - March 1 at 7:07 PM |
| Miragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 24 at 9:54 AM |
| Miragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 Shares
www.americanbankingnews.com - February 13 at 6:46 PM |
| Bruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) Stock
www.americanbankingnews.com - February 13 at 6:10 PM |
| Analysts Expect Miragen Therapeutics, Inc. (MGEN) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - February 13 at 3:14 AM |
| miRagen Therapeutics, Inc. Prices Public Offering of Common Stock
finance.yahoo.com - February 9 at 5:01 AM |
| miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering
www.streetinsider.com - February 5 at 3:08 PM |
| miRagen Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 5 at 3:08 PM |
| Miragen Therapeutics (MGEN) Rating Reiterated by Cann
www.americanbankingnews.com - February 2 at 4:46 PM |
| Miragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 30 at 9:39 AM |
| Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Quarterly Sales of $1.22 Million
www.americanbankingnews.com - January 29 at 8:22 AM |
Miragen Therapeutics (NASDAQ:MGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Miragen Therapeutics (NASDAQ:MGEN) Income Statement, Balance Sheet and Cash Flow Statement
Miragen Therapeutics (NASDAQ MGEN) Stock Chart for Friday, April, 20, 2018
Loading chart…
